On Wednesday, Eli Lilly And Co. (NYSE:LLY) announced a $4.5 billion investment to create the Lilly Medicine Foundry, a new ...
The EU's medicine watchdog recently declined to approve lecanemab and is still reviewing donanemab. These Alzheimer's treatments, approved in the US last year and developed by Biogen and Eli Lilly, ...
Annovis is at the forefront, testing buntanetap in pivotal clinical trials as a therapy for Alzheimer's and Parkinson's diseases (PD). Company has filed three new patents protecting combinations of ...